Japanese pharma major Takeda (TYO:4502) and Massachusetts, USA-based firm AC Immune (Nasdaq: ACIU) have inked a major new licensing deal.
The exclusive, worldwide option and license agreement relates to AC Immune’s active immunotherapies targeting toxic forms of amyloid beta.
Looking to make an impact in the growing area of Alzheimer’s disease treatment, Takeda will pick up rights to the immunotherapy ACI-24.060 through the deal.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze